News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2020

25 March, 2020 KALLELSE TILL ÅRSSTÄMMA I PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
1 March, 2020 PledPharma places dosing of patients in the POLAR program on hold News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox
18 February, 2020 Year-end report January-December 2019 News English Regulatory MAR Report Interim Yearend IR Optional
23 January, 2020 PledPharma provides update on the clinical POLAR program, clinical hold in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox
8 January, 2020 PledPharma to initiate one pivotal Phase II/III study with Aladote® for marketing authorisation application in both US and EU News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote

2019

16 December, 2019 Global phase III study POLAR-A fully recruited News Corporate Information Other Corporate Information English IR Optional mfn-cus-pledox
10 December, 2019 PLEDPHARMA’S ASIAN PARTNER SOLASIA ENTERS AGREEMENT WITH JAPANESE MARUHO FOR COMMERCIALIZATION OF PLEDOX® News Corporate Information Other Corporate Information English IR Optional mfn-cus-pledox
31 October, 2019 Trading in PledPharma's shares commences today on the Nasdaq Stockholm main market News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
29 October, 2019 PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
23 October, 2019 Interim report January-September 2019 News English Regulatory MAR Report Interim Q3 IR Optional
21 October, 2019 Nomination Committee appointed for the 2020 Annual General Meeting in PledPharma News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
16 October, 2019 PledPharma approved for listing on Nasdaq Stockholm News Corporate Action Other English Regulatory MAR IR Optional
9 October, 2019 PledPharma and Solasia enter a second license agreement for the development and commercialisation of PledOx® in Asia, targeting neuropathy caused by taxanes and any other chemotherapy News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-pledox
21 August, 2019 Half-Year report January-June 2019 News English Regulatory MAR Report Interim Q2 IR Optional
15 July, 2019 The Lancet EBioMedicine publishes Aladote® study results News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote
11 July, 2019 Aladote® – regulatory interactions News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote
31 May, 2019 PledPharma presents PledOx®’s global phase III program at ASCO News Corporate Information Presentation English IR Optional mfn-cus-pledox
21 May, 2019 PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
21 May, 2019 PledPharma announces intention of a Directed New Share Issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional
7 May, 2019 Report from the Annual General Meeting of PledPharma News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
6 May, 2019 Interim report January-March 2019 News English Regulatory MAR Report Interim Q1 IR Optional
12 April, 2019 PledPharma's drug candidate Aladote® is highlighted at one of the largest liver conferences globally News Corporate Action Other English IR Optional mfn-cus-aladote
8 April, 2019 NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
8 April, 2019 PledPharma’s 2018 annual report published News English Regulatory Listing Regulation Report Annual IR Optional
26 March, 2019 Data from the POP study support further development of Aladote® as a new treatment option for reducing liver damage due to paracetamol overdose News Corporate Information Presentation English IR Optional mfn-cus-aladote
PreviousNext

Calendar and upcoming reports

August 21, 2026 (7:00am CEST)
Interim Report Q2 2026

November 6, 2026 (7:00am CET)
Interim Report Q3 2026

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]